News
16h
InvestorsHub on MSNGilead Shares Slip on Reports of Planned Dismissal of Preventive Health Panel
Shares of Gilead Sciences (NASDAQ:GILD) dropped 2.8% Monday morning after reports emerged that U.S. Health and Human Services ...
Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...
20h
GlobalData on MSNGilead wins positive European approval opinion for twice-yearly HIV injection
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...
Investing.com -- { {6365|Gilead Sciences (NASDAQ: GILD )}} stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...
Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...
Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...
Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results